{"date":"2026-07-17","count":14,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4153-2026-07-17-1803-1nku9vi","company_id":"4153","company":"鈺緯","market":"上櫃","industry":"生技醫療","date":"2026-07-17","time":"18:03:29","subject":"公告本公司民國115年第2季財務報告董事會預計召開日期為民國115年7月27日","clause":"第31款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：鈺緯（4153），2026-07-17 18:03，「公告本公司民國115年第2季財務報告董事會預計召開日期為民國115年7月27日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8279-2026-07-17-1736-gif1qg","company_id":"8279","company":"生展","market":"上櫃","industry":"生技醫療","date":"2026-07-17","time":"17:36:58","subject":"公告115年第2季財務報告董事會召開日期","clause":"第31款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：生展（8279），2026-07-17 17:36，「公告115年第2季財務報告董事會召開日期」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7725-2026-07-17-1736-rlixyl","company_id":"7725","company":"列特博","market":"興櫃","industry":"生技醫療","date":"2026-07-17","time":"17:36:20","subject":"公告本公司財務暨會計主管異動","clause":"第11款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：列特博（7725），2026-07-17 17:36，「公告本公司財務暨會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6762-2026-07-17-1726-118ul62","company_id":"6762","company":"達亞","market":"上櫃","industry":"生技醫療","date":"2026-07-17","time":"17:26:21","subject":"115年第二季財務報告董事會預計召開日期為115年07月27日","clause":"第31款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：達亞（6762），2026-07-17 17:26，「115年第二季財務報告董事會預計召開日期為115年07月27日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4735-2026-07-17-1710-1cemc3i","company_id":"4735","company":"豪展","market":"上櫃","industry":"生技醫療","date":"2026-07-17","time":"17:10:27","subject":"公告本公司一年內累積取得同一有價證券達本公司實收資本額20%以上","clause":"第20款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：豪展（4735），2026-07-17 17:10，「公告本公司一年內累積取得同一有價證券達本公司實收資本額20%以上」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6666-2026-07-17-1702-ps7z81","company_id":"6666","company":"羅麗芬-KY","market":"上市","industry":"生技醫療","date":"2026-07-17","time":"17:02:30","subject":"公告本公司獨立董事辭任功能性委員會職務","clause":"第6款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：羅麗芬-KY（6666），2026-07-17 17:02，「公告本公司獨立董事辭任功能性委員會職務」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6666-2026-07-17-1702-qrsqda","company_id":"6666","company":"羅麗芬-KY","market":"上市","industry":"生技醫療","date":"2026-07-17","time":"17:02:09","subject":"公告本公司獨立董事辭任","clause":"第6款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：羅麗芬-KY（6666），2026-07-17 17:02，「公告本公司獨立董事辭任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4744-2026-07-17-1657-vnb9t6","company_id":"4744","company":"皇將","market":"上櫃","industry":"生技醫療","date":"2026-07-17","time":"16:57:20","subject":"公告智慧財產及商業法院民事裁定","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：皇將（4744），2026-07-17 16:57，「公告智慧財產及商業法院民事裁定」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-07-17-1602-ucplmz","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-07-17","time":"16:02:47","subject":"公告本公司股票面額變更為新台幣1元之變更登記已取得經濟部核准","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-07-17 16:02，「公告本公司股票面額變更為新台幣1元之變更登記已取得經濟部核准」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6469-2026-07-17-1432-vz3nrk","company_id":"6469","company":"大樹","market":"上櫃","industry":"生技醫療","date":"2026-07-17","time":"14:32:08","subject":"公告本公司調整股票股利暨現金股利之配股配息率","clause":"第14款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：大樹（6469），2026-07-17 14:32，「公告本公司調整股票股利暨現金股利之配股配息率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1760-2026-07-17-1422-8293ml","company_id":"1760","company":"寶齡富錦","market":"上市","industry":"生技醫療","date":"2026-07-17","time":"14:22:23","subject":"本公司PBF-1681 Tablet\"鐵易腎膜衣錠\"新療效暨新劑型新藥取得衛生福利部新藥查驗登記核准","clause":"第10款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：寶齡富錦（1760），2026-07-17 14:22，「本公司PBF-1681 Tablet\"鐵易腎膜衣錠\"新療效暨新劑型新藥取得衛生福利部新藥查驗登記核准」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2026-07-17-1400-1iz8ta0","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2026-07-17","time":"14:00:16","subject":"生華科新藥CX-5461首次聯合BeOne Medicines(百濟神州)已上市免疫檢查點抑制劑Tislelizumab治療多項晚期或轉移性實體腫瘤人體臨床試驗已向台灣TFDA提出IND申請。","clause":"第53款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2026-07-17 14:00，「生華科新藥CX-5461首次聯合BeOne Medicines(百濟神州)已上市免疫檢查點抑制劑Tislelizumab」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6939-2026-07-17-0851-9rbm9a","company_id":"6939","company":"啟弘生技","market":"興櫃","industry":"生技醫療","date":"2026-07-17","time":"08:51:40","subject":"公告修正本公司114年度股東會年報部分內容","clause":"第44款","fact_date":"2026-07-16","cite_as":"公開資訊觀測站重大訊息：啟弘生技（6939），2026-07-17 08:51，「公告修正本公司114年度股東會年報部分內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6543-2026-07-17-0835-17mtdio","company_id":"6543","company":"普惠醫工","market":"興櫃","industry":"生技醫療","date":"2026-07-17","time":"08:35:41","subject":"公告修正本公司114年度年報部份內容","clause":"第44款","fact_date":"2026-07-17","cite_as":"公開資訊觀測站重大訊息：普惠醫工（6543），2026-07-17 08:35，「公告修正本公司114年度年報部份內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}